Tools & Techniques for the Study of Biologics & Antibody Drug Conjugates
Broadcast date: March 27, 2024On-demand
Ryan Holly, PhD
Ryan Holly is the technical lead for the Targeted Protein Degradation program at Thermo Fisher Scientific, developing reagents to help assess the function of this new class of therapeutics. He received his doctorate in Chemistry and Biochemistry from the University of Oregon with a focus on molecular biology. In 2020, he joined Thermo Fisher Scientific as an R&D Staff Scientist to help drive the development of next-generation imaging reagents.
Close
Optimize your biotherapeutic discovery workflows by employing high-throughput methods for screening antibody binding and internalization, and learn techniques to precisely visualize internalization of antibodies.
In this webinar, you will learn:
- About sensitive, rapid, and high-throughput methods to screen for antibody binding and internalization;
- Techniques to directly visualize the internalization of therapeutic antibodies and antibody-drug conjugates in live cells;
- How you can use these methods to discover and develop more biotherapeutic leads in your research.
The fundamental cellular mechanisms of internalization and trafficking are crucial to many areas of cell biology, especially the proper function of therapeutic antibodies.
Antibodies intended for use as antibody-drug conjugates (ADCs) should specifically bind to target cells and rapidly internalize via endocytosis.
However, the ability to study these processes has historically been limited by the lack of tools that directly monitor the internalization and subsequent catabolism of extracellular material.
This webinar will demonstrate sensitive, rapid, high-throughput methods to screen for antibody internalization. Additionally, we will present techniques to directly visualize the internalization of therapeutic antibodies and ADCs in live cells for structure-activity relationship studies.
We will also demonstrate how the insights provided by these approaches have the potential to accelerate biotherapeutic lead generation and development.
All emails contain an unsubscribe link.You can review our privacy policy, cookie policy and terms and conditions online.
